Insomnia Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Insomnia Treatment Market Expected to Reach US$ 5.1 Billion by 2031, with 4.3% CAGR during 2024-2031 Forecast Period

The global insomnia treatment market, valued at US$ 3.7 billion in 2022, is projected to witness substantial growth, reaching US$ 5.1 billion by 2031, with a steady Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period of 2024 to 2031.

Insomnia, a prevalent sleep disorder characterized by difficulty falling asleep, staying asleep, or obtaining quality sleep, has spurred the demand for effective treatments. Short-term insomnia, often triggered by stress or environmental changes, can persist for days or weeks, while chronic insomnia, occurring at least three nights per week for over three months, presents significant healthcare challenges.

The global market for insomnia treatment has experienced notable expansion, fueled by the uptake of benzodiazepine drugs such as estazolam, temazepam, and quazepam. Temazepam, in particular, stands out as the most frequently prescribed benzodiazepine for insomnia management, with drug selection based on desired onset and duration of action.

Factors propelling market growth include escalating stress levels, product innovations, and heightened research and development activities. Leading industry players like Merck & Co., Pfizer Inc., Abbott, Eisai Ltd., and Idorsia Pharmaceuticals are actively engaged in driving advancements within the market.

To know more Insights Download Sample: https://www.datamintelligence.com/download-sample/insomnia-treatment-market

Insomnia Treatment Market Dynamics:

Rising Stress Levels Among People Expected to Propel Market Growth

Mounting global stress levels serve as a primary growth driver, with stress and anxiety frequently leading to insomnia. Various psychological and physiological factors, including stressful life events and traumatic experiences, contribute to insomnia onset and persistence. Recent data from the Health and Safety Executive underscores this trend, revealing a significant proportion of individuals reporting work-related stress, depression, or anxiety, alongside insomnia symptoms.

Rising FDA Approvals for Insomnia Treatment Expected to Drive Market Growth

Increasing approvals for insomnia treatments by regulatory bodies stimulate market expansion. Notably, Zydus Lifesciences Ltd's recent FDA approval for its generic version of Triazolam tablets exemplifies this trend, offering patients short-term relief from insomnia symptoms. Such approvals signal progress in addressing unmet medical needs within the insomnia treatment landscape.

Side Effects Associated with Insomnia Drugs Pose Market Challenges

While insomnia medications offer relief, they can also induce adverse effects such as constipation, dry mouth, and headaches. Moreover, the prevalence of daytime drowsiness and impaired cognitive function following medication use underscores the need for safer treatment options. These considerations present challenges for market growth.

Insomnia Treatment Market Segment Analysis:

Chronic Insomnia Dominates Market Share, Driven by Treatment Innovations

The global market for insomnia treatment is segmented based on type, treatment, distribution channel, and region. Chronic insomnia, accounting for approximately 47.3% of the market share, reflects growing demand driven by treatment innovations. Recent launches such as Idorsia Ltd's QUVIVIQ and Eisai Co., Ltd.'s DAYVIGO highlight advancements in chronic insomnia management, offering patients improved symptom relief and enhanced daytime functionality.

Insomnia Treatment Market Geographical Share:

North America Leads Market Share, Sustained by Research and Awareness Efforts

North America maintains a significant market share, attributable to factors including the rising prevalence of sleep disorders and ongoing research initiatives. The Sleep Foundation estimates a substantial proportion of the U.S. population suffers from sleep disorders, with insomnia affecting daily activities in a notable percentage of adults. These trends underscore North America's dominance in the global insomnia treatment market.

Insomnia Treatment Market Key Players:

Major industry players shaping the global market landscape include Merck & Co., Pfizer Inc., Abbott, and Eisai Ltd., among others. These companies remain pivotal in driving innovation and addressing evolving patient needs within the insomnia treatment space.

Related Reports:

Multiple sclerosis therapeutics market: https://datamintelligence.com/research-report/multiple-sclerosis-therapeutics-market
Insulinoma treatment market : https://datamintelligence.com/research-report/insulinoma-treatment-market
Ear infection treatment market : https://datamintelligence.com/research-report/ear-infection-treatment-market
Pneumonia therapeutics market : https://datamintelligence.com/research-report/pneumonia-therapeutics-market
Proton pump inhibitors market: https://datamintelligence.com/research-report/proton-pump-inhibitors-market
Myelofibrosis therapeutics market : https://datamintelligence.com/research-report/myelofibrosis-therapeutics-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.